IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Remus Pharmaceuticals IPO is a book build IPO listing on NSE EMERGE exchange. The company is based in Ahmedabad and caters to Pharmaceutical sector. Beeline Capital Advisors Private is the merchant banker of Remus Pharmaceuticals IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 10th March 2023.
Remus Pharmaceuticals IPO posted revenues of Rs 44.81 crores and PAT of Rs 8.59 crores in FY23 on annualised basis.Financial results of Remus Pharmaceuticals IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Remus Pharmaceuticals IPO PAT Margin is 19.13%, ROCE (Return on Capital Employed) is 28.01% as per latest financial. The below table shows Remus Pharmaceuticals IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Remus Pharmaceuticals IPO is Rs 181.03 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Remus Pharmaceuticals IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Remus Pharmaceuticals IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Remus Pharmaceuticals IPO is ₹181.03 Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Remus Pharmaceuticals IPO has a Price-to-Earnings (PE) ratio of 21.09 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Remus Pharmaceuticals IPO reported revenue of ₹44.81 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Remus Pharmaceuticals IPO provide insights into sales growth, market demand, and business scalability.
Remus Pharmaceuticals recorded an EBITDA of ₹ 12.21 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Remus Pharmaceuticals Profit After Tax (PAT) is ₹8.57 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 44.81 Cr.
EBITDA Margin:
27.25
%
Net Worth: ₹ 17.12 Cr.
Market Capitalisation:
₹ 181.03 Cr.
P/E:
21.09 times
P/BV: 2.79 times
EV/EBITDA: 15.16 times
Remus Pharmaceuticals operates in Pharmaceutical and Marketing And Distribution Pharmaceutical Drugs. The Issue is listed on NSE EMERGE in May, 2023. Remus Pharmaceuticals IPO size was 47.69 with Issue price of 1229.00 .
Merchant Banker(s) of Remus Pharmaceuticals IPO: Beeline Capital Advisors Private Limited
Remus Pharmaceuticals IPO subscription was 57.21 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Remus Pharmaceuticals IPO listed at a listing price of 1711.00 against the offer price of 1229.00.
The current market price of Remus Pharmaceuticals is 2004.00.
Why Us?
